Literature DB >> 15709176

Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.

Sonia M Boyapati1, Xiao-Ou Shu, Zhi Xian Ruan, Qiuyin Cai, Jeffrey R Smith, Wanqing Wen, Yu-Tang Gao, Wei Zheng.   

Abstract

PURPOSE: The effects of estrogens are mediated primarily through estrogen receptor (ER) in breast tissue, and polymorphisms in the ER genes may alter the functions of these receptors. Polymorphisms in the ER-alpha gene have been reported to be associated with breast cancer risk. However, to our knowledge, no study has been published on the relation between ER-alpha gene polymorphisms and breast cancer survival. EXPERIMENTAL
DESIGN: To determine whether three common polymorphisms in the ER-alpha gene, PvuII, XbaI, and GT dinucleotide repeats are associated with breast cancer survival, we evaluated data from a cohort of 1,069 breast cancer patients who participated in the Shanghai Breast Cancer Study between 1996 and 1998. The median follow-up time for this cohort of women was 5.2 years.
RESULTS: No overall association was observed between ER gene polymorphisms and breast cancer survival. The genotype associations, however, were modified by ER status in breast cancer tissues. Comparing those with the PP genotype to the pp genotype of the PvuII polymorphism, the hazard ratios (HR) of dying were 3.30 [95% confidence interval (95% CI), 1.42-7.69] and 0.54 (95% CI, 0.24-1.23), respectively, for participants with ER-negative breast cancer and ER-positive breast cancer. Similarly, compared with those with no (GT)(23) alleles, carrying one or two (GT)(23) alleles of the GT repeat polymorphism was related to a HR of 1.48 (95% CI, 0.77-2.87) for ER-negative breast cancer and a HR of 0.25 (95% CI, 0.09-0.69) for ER-positive cancer. The effect of ER on breast cancer survival was also modified by genotypes of ER-alpha gene. Tests for multiplicative interaction were highly significant.
CONCLUSIONS: These data suggest that the ER-alpha gene polymorphisms and ER status may have an interactive effect on breast cancer survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709176

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Estrogen receptor alpha polymorphisms and the risk of malignancies.

Authors:  Andrei Anghel; Diana Narita; Edward Seclaman; Emilian Popovici; Mariana Anghel; Liviu Tamas
Journal:  Pathol Oncol Res       Date:  2010-04-11       Impact factor: 3.201

2.  Reported early family environment covaries with menarcheal age as a function of polymorphic variation in estrogen receptor-α.

Authors:  Stephen B Manuck; Anna E Craig; Janine D Flory; Indrani Halder; Robert E Ferrell
Journal:  Dev Psychopathol       Date:  2011-02

3.  Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.

Authors:  Shilpi Chattopadhyay; Sarah Siddiqui; Md Salman Akhtar; Mohammad Zeeshan Najm; S V S Deo; N K Shukla; Syed Akhtar Husain
Journal:  Tumour Biol       Date:  2014-01-16

4.  Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer.

Authors:  Huai-Lu Chang; Yu-Jen Cheng; Chung-Kuang Su; Meng-Chih Chen; Fu-Hsin Chang; Fu-Gong Lin; Li-Feng Liu; Shyng-Shiou F Yuan; Ming-Chih Chou; Chien-Fu Huang; Chi-Chiang Yang
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

5.  ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Authors:  Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Vernon Harvey; Patrick Neven; Laurent Arnould; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan
Journal:  Breast Cancer Res Treat       Date:  2015-11-21       Impact factor: 4.872

6.  Active and passive smoking, IL6, ESR1, and breast cancer risk.

Authors:  Martha L Slattery; Karen Curtin; Anna R Giuliano; Carol Sweeney; Richard Baumgartner; Sandra Edwards; Roger K Wolff; Kathy B Baumgartner; Tim Byers
Journal:  Breast Cancer Res Treat       Date:  2007-06-27       Impact factor: 4.872

7.  A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.

Authors:  Zhen Hu; Chuan-Gui Song; Jing-Song Lu; Jian-Min Luo; Zhen-Zhou Shen; Wei Huang; Zhi-Ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-12       Impact factor: 4.553

8.  Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.

Authors:  Yan Jin; Daniel F Hayes; Lang Li; Jason D Robarge; Todd C Skaar; Santosh Philips; Anne Nguyen; Anne Schott; Jill Hayden; Suzanne Lemler; Anna Maria Storniolo; David A Flockhart; Vered Stearns
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

9.  Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women.

Authors:  Carolyn J Crandall; Mary E Sehl; Sybil L Crawford; Ellen B Gold; Laurel A Habel; Lesley M Butler; Maryfran R Sowers; Gail A Greendale; Janet S Sinsheimer
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

10.  Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.

Authors:  N L Henry; A Nguyen; F Azzouz; L Li; J Robarge; S Philips; D Cao; T C Skaar; J M Rae; A M Storniolo; D A Flockhart; D F Hayes; V Stearns
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.